Antibodies
10 February 2010
Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day9 February 2010
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients9 February 2010
Phase I Trial Commences Treating Patients with Pancreatic and Colorectal Cancer Using Novel Monoclonal Antibody8 February 2010
Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche5 February 2010
TenX Biopharma Licenses Zanolimumab From Genmab4 February 2010
BTG Receives First European Regulatory Approval for DigiFab2 February 2010
Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer29 January 2010
Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option Fund29 January 2010
Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer28 January 2010
Patrys to work with CSL to explore antibody drugs28 January 2010
Pacgen Signs Research Collaboration Agreements27 January 2010
MorphoSys Licenses HuCAL PLATINUM Antibody Library to Shionogi in Research Partnership26 January 2010
YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA25 January 2010
ASCO-GI: Overall Survival With Erbitux Is Significantly Improved in Patients With KRAS Wild-Type Tumors in CRYSTAL22 January 2010
Arzerra (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia21 January 2010
Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium20 January 2010
Fully Human Monoclonal Anti-TNF-alpha Antibody HUMIRA Receives Approval as Japan’s First Biological Agent for Psoriasis19 January 2010
MorphoSys Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid Arthritis19 January 2010
Enrollment Open for Clinical Trial of Cytolin, a Novel Immune Therapy from CytoDyn for Treating Early HIV Infection19 January 2010
Perseid Achieves Preclinical Milestone Under Collaboration with Astellas for CTLA-4 ProgramNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports